Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson’s Disease (CAPTURE PD): Protocol for a Multicenter Study by Timo, Siepmann et al.
May 2017 | Volume 8 | Article 2121
Protocols
published: 26 May 2017
doi: 10.3389/fneur.2017.00212
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Valdir Andrade Braga, 
Federal University of 
Paraíba, Brazil
Reviewed by: 
Francisco A. Gondim, 
Federal University 
of Ceará, Brazil  
Thiago S. Moreira, 
University of São Paulo, Brazil
*Correspondence:
Timo Siepmann 
Timo.Siepmann@uniklinikum-
dresden.de
Specialty section: 
This article was submitted to 
Autonomic Neuroscience, 
a section of the journal 
Frontiers in Neurology
Received: 21 February 2017
Accepted: 01 May 2017
Published: 26 May 2017
Citation: 
Siepmann T, Pintér A, Buchmann SJ, 
Stibal L, Arndt M, Kubasch AS, 
Kubasch ML, Penzlin AI, Frenz E, 
Zago W, Horváth T, Szatmári S Jr, 
Bereczki D, Takáts A, Ziemssen T, 
Lipp A, Freeman R, Reichmann H, 
Barlinn K and Illigens BM-W (2017) 
Cutaneous Autonomic Pilomotor 
Testing to Unveil the Role of 
Neuropathy Progression in Early 
Parkinson’s Disease (CAPTURE PD): 
Protocol for a Multicenter Study. 
Front. Neurol. 8:212. 
doi: 10.3389/fneur.2017.00212
cutaneous Autonomic Pilomotor 
testing to Unveil the role of 
Neuropathy Progression in Early 
Parkinson’s Disease (cAPtUrE PD):
Protocol for a Multicenter study
 
Timo Siepmann1*, Alexandra Pintér 2, Sylvia J. Buchmann3,4, Leonie Stibal3, Martin Arndt1, 
Anne Sophie Kubasch5, Marie Luise Kubasch1,3, Ana Isabel Penzlin1, Elka Frenz1, 
Wagner Zago6, Tamás Horváth7, Szabolcs Szatmári Jr.8, Dániel Bereczki8,  
Annamária Takáts8, Tjalf Ziemssen1, Axel Lipp4, Roy Freeman3, Heinz Reichmann1,  
Kristian Barlinn1 and Ben Min-Woo Illigens3
1 Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, 
2 Department of Family Medicine, Semmelweis University, Budapest, Hungary, 3 Department of Neurology, Beth Israel 
Deaconess Medical Center, Harvard Medical School, Boston, MA, United States, 4 Department of Neurology, Charite 
University Medicine Berlin, Berlin, Germany, 5 Center for Rare Diseases, University Hospital Carl Gustav Carus, Technische 
Universität Dresden, Dresden, Germany, 6 Prothena Biosciences Inc., Portland, OR, United States, 7 Department of 
Hydrodynamic Systems, Budapest University of Technology and Economics, Budapest, Hungary, 8 Department of Neurology, 
Semmelweis University, Budapest, Hungary
Background: In Parkinson’s disease (PD), alpha-synuclein accumulation in cutaneous 
autonomic pilomotor and sudomotor nerve fibers has been linked to autonomic ner-
vous system disturbances even in the early stages of the disease. This study aims to 
assess the association between alpha-synuclein-mediated structural autonomic nerve 
fiber damage and function in PD, elucidate the role of neuropathy progression during 
the early disease stages, and test reproducibility and external validity of pilomotor 
function assessment using quantitative pilomotor axon-reflex test and sudomotor 
function via quantitative direct and indirect test of sudomotor function.
Methods/design: A prospective controlled study will be conducted at four study sites 
in Europe and the USA. Fifty-two male and female patients with idiopathic PD (Hoehn 
and Yahr 1–2) and 52 age- and sex-matched healthy controls will be recruited. Axon-
reflex-mediated pilomotor erection will be induced by iontophoresis of phenylephrine on 
the dorsal forearm. Silicone impressions of the response will be obtained, scanned, and 
quantified for pilomotor muscle impressions by number, impression size, and area of 
axon-reflex spread. Axon-reflex-mediated sweating following acetylcholine iontophoresis 
will be quantified for number and size of droplets and axon-reflex spread. Sympathetic 
skin responses, autonomic and motor symptoms will be evaluated. Tests will be per-
formed at baseline, after 2 weeks, 1, 2, and 3 years. Skin biopsies will be obtained at 
baseline and after 3 years and will be analyzed for nerve fiber density and alpha-synuclein 
accumulation.
Abbreviations: UPDRS, Unified Parkinson’s Disease Rating Scale; PD, Parkinson’s disease; PGP, protein gene product; QDIRT, 
quantitative direct and indirect test of sudomotor function; QPART, quantitative pilomotor axon-reflex test; QSART, quan-
titative sudomotor axon-reflex test; SCOPA-AUT, scale for outcomes in Parkinson’s disease for autonomic symptoms; SSR, 
sympathetic skin response; SCL, skin conductance level.
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Discussion: We anticipate that progression of autonomic nerve dysfunction assessed 
via pilomotor and sudomotor axon-reflex tests is related to progression of autonomic 
symptom severity and alpha-synuclein deposition. Potential applications of the tech-
niques include interventional studies evaluating disease-modifying approaches and 
clinical assessment of autonomic dysfunction in patients with PD.
clinical trail registration: TRN NCT03043768.
Keywords: autonomic, Parkinson’s disease, diagnosis, pilomotor, axon-reflex
INtroDUctIoN
Background
In patients with Parkinson’s disease (PD), early diagnosis enables 
timely symptomatic treatment and improvement of quality of life 
(1). However, diagnosis of prodromal and early disease stages is 
challenging since only few diagnostic techniques are available (2). 
Symptoms due to dysregulation of autonomic nervous system 
functions such as impaired thermoregulation and cardiovascular 
symptoms are prevalent in patients with PD. In fact, these symp-
toms frequently precede onset of motor symptoms and reduce 
quality of life (2). The pathophysiological mechanisms leading 
to autonomic disturbances in patients with PD disease are not 
fully understood. However, there is accumulating evidence of 
alpha-synuclein-mediated damage to autonomic postganglionic 
adrenergic and cholinergic skin nerve fibers (3–5). A recent paper 
of Wang and colleagues showed that non-specific nerve fiber 
stain protein gene product 9.5 (PGP) in epidermal biopsies is 
reduced whereas the number of alpha synuclein positive fibers is 
increased in PD patients compared to healthy subjects (6). This 
study also showed that the alpha synuclein/PGP ratio is increased 
in cutaneous sudomotor and pilomotor fibers in PD patients 
and that higher alpha-synuclein/PGP ratios are associated with 
more severe autonomic dysfunction and more advanced motor 
symptoms. Importantly, a clear increase in pathology was seen 
between Hoehn and Yahr 1 and 2, suggesting a possible utility in 
relatively short clinical studies. Although it may be concluded that 
quantification of alpha-synuclein deposition in pilomotor muscles 
is a valid biomarker for PD, this technique is limited by its invasive 
nature and by the uncertainty of whether the alpha-synuclein 
staining detected in the nerves is, indeed, the cause of the observed 
symptomatic functional deficits.
Autonomic skin nerve fibers can not only be quantitatively 
assessed for structural damage but also function. In fact, 
functional assessment of autonomic skin nerves has taken on 
increasing importance in the evaluation of autonomic neu-
ropathy (7–9). Cutaneous unmyelinated C-fibers and lightly 
myelinated A-delta fibers (small fibers) are responsive to a 
range of physical, chemical, and mechanical stimuli that can 
induce an axon-reflex mediated response. The axon-reflex was 
first described in vasomotor small fibers. Activation of these 
postganglionic cutaneous fibers results in orthodromic conduc-
tion to the spinal cord and antidromic conduction to other axon 
branches. On activation, both C-fibers and A-delta fibers release 
SP and CGRP leading to vasodilation and plasma extravasa-
tion (10–12). This neurally mediated response can be evoked 
by chemical (e.g., acetylcholine, histamine and capsaicin) and 
electrical stimulation (13, 14).
While quantification of vasomotor axon-reflex responses 
for diagnostic purposes is limited by interindividual vari-
ability, further developments focused on postganglionic small 
sudomotor fibers. The acetylcholine-induced sudomotor C-fiber 
axon-reflex also involves the stimulation of postganglionic 
sympathetic nerve terminals. Conversely to the vasomotor axon- 
reflex, an antidromic impulse travels to a branch point and then 
returns orthodromically to release acetylcholine from a neighboring 
nerve terminal. Acetylcholine diffuses across the neuroglandular 
junction and binds to muscarinic receptors on the eccrine sweat 
glands and evokes a sweat response (8, 15, 16). The sudomotor 
axon-reflex can be quantified by the quantitative sudomotor 
axon-reflex test (QSART) and the quantitative direct and 
indirect test of sudomotor function (QDIRT) (16, 17). QSART 
assesses axon-reflex-mediated sweating with temporal resolu-
tion but is limited by demanding technical settings and absence 
of spatial resolution. QDIRT quantifies axon-reflex-mediated 
sweating with both temporal and spatial resolution and requires 
less demanding technical setting (15). The role of small fiber-
mediated sudomotor dysfunction in PD is poorly elucidated. 
Several studies indicated impairment of sudomotor function 
even in early disease stages when evaluated via sympathetic 
skin response (SSR), a technique which assesses skin conduct-
ance levels (SCLs) following sympathetic stimulation with high 
sensitivity but is limited by high interindividual variability and 
the absence of differentiation between pre-and postganglionic 
function (18–20). However, another study of SSR showed not 
such impairment in PD patients without autonomic symptoms, 
suggesting that the technique is not sufficient for exploration of 
subclinical autonomic dysfunction in early PD (21). Another 
approach to quantify small fiber neuropathy is the skin wrin-
kling test, which includes hand immersion in heated saline and 
subsequent visual grading of skin wrinkling. The technique has 
been used in patients with PD and Parkinsonism, but this study 
was limited by the absence of healthy controls. The technique is 
easy to use and inexpensive. However in this study, it remained 
unclear to what degree observed differences in wrinkling of 
the skin did reflect postganglionic small nerve fiber function 
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rather than large fiber integrity limiting interpretability of the 
results (22).
Only few data are available on postganglionic small fiber 
function in PD and, to date, there are no studies of sudomotor 
axon-reflex response with temporal and spatial resolution in 
this prevalent synucleinopathy (23). Whereas the sudomotor 
axon-reflex response is a postganglionic cholinergic function, 
pilomotor erection is executed via postganglionic noradrenergic 
fibers (17, 24).
This multicenter protocol is based on previous studies of pilo-
motor erection that have been undertaken by two of the study 
groups involved in the design of the present protocol. First, 
we demonstrated that iontophoretic stimulation of cutaneous 
adrenergic small fibers with phenylephrine elicits axon-reflex-
mediated pilomotor erection (goose bumps) in an indirect 
region surrounding the area of direct stimulation, which can 
be evaluated using the Quantitative Pilomotor Axon-Reflex Test 
(QPART) (24). In another investigation of pilomotor function 
in patients with PD versus healthy control subjects, we showed 
that functional integrity of pilomotor nerve fibers is impaired 
in early stages of PD and correlates negatively with severity 
of autonomic symptoms (25). Taken together, the data deriv-
ing from our previous investigations indicate that pilomotor 
axon-reflex assessment might be useful in the investigation of 
disease-related pathology and supplement other clinical mark-
ers of autonomic neuropathy in PD. However, the specific role 
or pilomotor and sudomotor nerve fiber damage in PD remains 
to be elucidated.
specific Aims
With the goal of developing novel endpoints for early stage trials 
of disease-modifying therapies in PD, specific aim of this study is 
to assess reproducibility, external validity of QPART and QDIRT 
in the evaluation of patients with PD. Moreover, this study aims 
to assess the hypothesis that functional impairment in pilomotor 
and sudomotor nerve fibers in early PD relates to the extent of 
alpha-synuclein-mediated structural damage to these fibers and 
may, therefore, constitute a potential non-invasive biomarker for 
autonomic neuropathy in PD.
Protocol outline
This study is designed as a longitudinal, controlled, blinded, 
diagnostic multicenter study, and will be conducted at four 
study sites in Dresden, Germany (Department of Neurology, 
University Hospital Carl Gustav Carus, coordinating site), 
Boston, USA (Department of Neurology Beth Israel Deaconess 
Medical Center, core lab for data analysis), Budapest, Hungary 
(Department of Neurology, Semmelweis University) and Berlin, 
Germany (Department of Neurology, Charite University Medicine 
Berlin).
Patients with early PD and age and gender-matched healthy 
control subjects will be longitudinally evaluated for functional 
and structural damage to pilomotor and sudomotor skin nerve 
fibers over a period of 3 years. SSRs will be evaluated as com-
parative measure of sudomotor function. Details on the timeline 
and applied study techniques are listed in the Section “Stepwise 
Procedures” (paragraph 3).
MAtErIAls AND EQUIPMENt
The study procedures applied in this protocol will employ equip-
ment and materials as listed below separately for each study 
procedure.
Quantitative Pilomotor Axon-reflex test
Materials and equipment used for the QPART include an ion-
tophoresis stimulation box (Phoresor II-Auto-PM850; IOMED 
Inc., Salt Lake City, UT, USA), disposable drug delivery capsule 
electrodes (LI-611; Perimed®, Järfälla, Sweden), 0.01% phenyle-
phrine solution, silicone-based two-phase material (Silasoft®; 
Microsonic Inc., Ambridge, PA, USA), a high resolution scanner 
connected to a personal computer equipped with image analyz-
ing software (Fuel3D® Studio Starter; Fuel 3D® Technologies 
Limited, Chinnor, UK).
Quantitative Direct and Indirect test of 
sudomotor Function
Materials and equipment used for the QDIRT include an ion-
tophoresis stimulation box (Phoresor II-Auto-PM850; iOMED 
Inc., Salt Lake City, UT, USA), disposable drug delivery capsule 
electrodes (LI-611; Perimed®, Järfälla, Sweden), 10% acetylcho-
line solution, indicator dye consisting of providine iodine and 
corn starch, an 18 Megapixel Camera (EOS 60D; Canon Inc., 
Tokyo, Japan), with 100-mm macro lens, a personal computer 
equipped with image analyzing software (Image Pro® Plus 6.0; 
Media Cybernetics Inc., Rockville, MD, USA).
sympathetic skin response
Sympathetic Skin Response is measured using a polygraph 
(PowerLab; ADInstruments, Bella Vista, NSW, Australia).
stEPWIsE ProcEDUrEs
list of stepwise study Procedures
Subjects will be assessed for eligibility by a listed study physician. 
Eligible subjects will be informed in detail about the study protocol 
and each applied study procedure as well as the risks of each pro-
cedure. Oral and written informed consent will be obtained from 
each subject. At baseline, all subjects will undergo medical history, 
physical examination; specific study procedures as described in 
the Section “Study Techniques.” These testing procedures will be 
repeated, after 1–2 weeks, 1, 2, and 3 years post-baseline. All test-
ing will be performed in a temperature and humidity controlled 
environment. Only at one site (Dresden, Germany), subjects 
will additionally undergo the skin punch biopsy procedure as 
described above at baseline, after 1 and 3 years. The timeline of 
this study is illustrated in detail in Table 1.
selection of subjects
Thirteen patients with PD and 13 healthy control subjects will 
be recruited at each participating site. Patients will be recruited 
from university hospital-based PD outpatient clinics at each site. 
Control subjects will be recruited through local advertising at 
tABlE 1 | A table of stepwise study procedures in chronological order.
Procedure Baseline 1–2 weeks 12 months 24 months 36 months
Medical history, physical examination x
Quantitative pilomotor axon-reflex test x x x x x
Sympathetic skin response x x x x x
Quantitative direct and indirect test of sudomotor function x x x x x
UPDRS x x x x x
SCOPA-AUT x x x x x
Biopsies (only at one site) x x x
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university hospitals. Male and female PD patients [idiopathic 
parkinsonism, Hoehn and Yahr (H and Y) scores 1–2] aged 
35–80 years with mild motor symptoms (Hoehn and Yahr 1–2) 
and age- and gender-matched healthy control subjects will 
be recruited at each site. We will exclude subjects who fulfill 
with one or more of the following criteria: any dermatological 
disorders affecting the cutaneous testing regions, treatment with 
tricyclic antidepressants, noradrenergic antidepressants, beta-
blockers, alpha-adrenergic agonists or antagonists, cholinergic 
or anticholinergic agents, known allergy to phenylephrine or 
acetylcholine, elevated alcohol consumption (more than four 
alcoholic beverages/week), nicotine consumption within the past 
5 years, known disorders affecting autonomic functions (includ-
ing diabetes, pure autonomic failure, inflammatory demyelinat-
ing polyradiculoneuropathies, multiple system atrophy, atypical 
Parkinson syndromes, body mass index over 25 kg/m2, acute or 
chronic renal disease, gout, rheumatoid arthritis, Lupus, Sjögren’s 
syndrome, Triple-A syndrome, autonomic neuropathies not 
related to PD). Additional exclusion criteria for healthy control 
subjects include any acute or chronic disease and chronic intake 
of medication. All subjects will be asked to avoid caffeine on the 
days of testing. Missing data due to missed follow-up visits will 
be minimized by monitoring of adherence as well as phone calls 
and e-mails prior to each follow-up.
MEtHoDs AND ANtIcIPAtED rEsUlts
study techniques
Quantitative Pilomotor Axon-Reflex Test
Iontophoresis of phenylephrine is used to induce axon-reflex-
mediated piloerection as previously described (24). Briefly, a drug 
delivery capsule electrode (LI-611, Perimed, Sweden) is affixed 
on the testing area on the dorsal forearm. The inner chamber of 
this capsule, open to the skin surface, is filled with 0.4 ml of 0.01% 
phenylephrine solution. The drug delivery electrode is then con-
nected to the iontophoresis stimulation box (Phoresor-PM850, 
IOMED, USA). Iontophoresis is performed over a 1-cm diameter 
skin region with 0.5  mA over 5  min. Silicone impressions of 
piloerection are obtained to create a local topographic map of 
piloerection. A silicone-based two-phase material with high 
liquidity (Honigum Light, DMG, Hamburg, Germany) is placed 
over the skin for 10 s. A dispensing device (Automix dispenser, 
DMG, Hamburg, Germany) is used to mix and apply both phases 
of the silicone in order to standardize application of silicone and 
avoid any mechanic pressure during the application process, 
thus further reducing sweating. The silicone cures for 5 min has 
toner applied to mark the pilomotor impressions, excess toner 
is wiped free, and the silicone is scanned to capture the image 
digitally. Blinded observers analyze silicone scans using image 
analyzing software (Image Pro Plus 6.0, Media Cybernetics, 
Bethesda, MD, USA). Silicone impressions of erect hair follicles 
are quantified by number and area. The outline of the total area 
of piloerection is defined as a line connecting the outer edges of 
the most peripheral erect hair follicle impressions. The indirect 
area of axon-reflex-mediated piloerection can be calculated by 
subtracting the area of phenylephrine application from the total 
area of piloerection. QPART is performed on both forearms 
and both lower legs. Potential artifacts of the method include 
confounding sweat droplets. This will be overcome by selecting a 
silicone material with high liquidity to minimize pressure to the 
skin as well as a short placement time of 10 s. We anticipate that 
pilomotor function is impaired in patients with PD compared to 
healthy subjects, is related to alpha-synuclein-mediated struc-
tural damage to pilomotor nerve fibers and progresses over time. 
The anticipated pathophysiological mechanism of pilomotor 
erection in healthy subjects and patients with PD is illustrated 
in Figure 1. Methodology of the silicone impression technique 
as well as anticipated differences between controls and PD are 
illustrated in Figure 2.
Quantitative Direct and Indirect Test of Sudomotor 
Function
Axon-reflex-mediated sweating is measured after iontophoresis 
of 10% acetylcholine by drying the stimulated region on the volar 
aspect of the forearm and dusting with indicator dye (povidone–
iodine and cornstarch) followed by repeated digital photographs 
taken every 15 s for 7 min (8 Megapixel or higher camera with 100-
mm macro lens). The QDIRT images are uploaded as a sequence 
and analyzed using an automated image analyzing algorithm 
as previously described (17). Sweat droplets in the axon-reflex 
region are quantified by number, size, and axon-reflex spread. 
Spatial spread of the axon-reflex-mediated sweating including 
the direct area of stimulation is calculated by defining the outline 
of the total area of sweating as a line connecting the outer edges 
of the most peripheral droplets. The direct area of acetylcholine 
application is then subtracted from the total area to calculate the 
axon-reflex area. QDIRT is performed on both forearms and 
both lower legs. A limitation of this study technique is that it has 
not been validated in patients with PD. Therefore, SSRs are also 
evaluated in this protocol as a less specific but well established 
comparative measure of sudomotor function. We anticipate that 
AB
FIgUrE 1 | (A) The mechanism whereby iontophoresis of phenylephrine induces a local neurogenic pilomotor erection (“goose bumps”). Receptor-mediated 
pilomotor erection is provoked in the cutaneous area of application (direct response), an action potential travels antidromically and then orthodromically to 
neighboring pilomotor muscles. Thus, pilomotor erection is evoked in an area outside the area of phenylephrine application (indirect response). Quantification of 
indirect pilomotor erection is a measure of functional integrity of pilomotor nerve fibers. (B) Reduced axon-reflex-mediated pilomotor erection due to alpha-synuclein-
mediated damage to the pilomotor nerve fiber (m: months, w: weeks). The figures were designed by TS and BMI.
5
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sudomotor function is impaired in patients with PD compared to 
healthy subjects, is related to alpha-synuclein-mediated structural 
damage to sudomotor nerve fibers, and progresses over time.
Sympathetic Skin Response
Sympathetic skin response is evaluated following sudden deep 
respiration as previously described (15) Briefly, the SCL is 
measured in μSiemens (μS) from two medial phalanges (index 
and third finger) with a Powerlab®polygraph (AD Instruments, 
Bella Vista, NSW, Australia). The maximum increase in ampli-
tude following sudden deep respiration (SSR) is calculated to 
quantify the functional reactivity of sweat glands. While the 
technique shows high sensitivity for changes in sweat output, 
drawbacks include high interindividual variability and the lack 
AB
FIgUrE 2 | (A) The stepwise procedures of evoking and quantifying pilomotor erection. Iontophoresis of phenylephrine is followed by obtaining silicone impressions 
of the pilomotor erection response. Impressions are highlighted and scanned. (B) Anticipated results (example observation from an unpublished pilot study) of a 
healthy subject versus a patient with Parkinson’s disease (PD). The comparison of scans illustrates the anticipated reduction of pilomotor axon-reflex spread in PD. 
The figures were designed by TS and BMI.
6
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of differentiation between pre- and postganglionic sudomo-
tor function (15). Therefore, sudomotor function will also 
be assessed by QDIRT, a specific measure of postganglionic 
sudomotor function, which previously showed low variability 
(17). We anticipate that SSR is reduced in patients with PD 
compared to healthy control subjects but the difference might 
be less pronounced than in QDIRT parameters due to high 
interindividual variability.
Skin Biopsies: Alpha-Synuclein/PGP Ratio
Immunhistochemical staining for alpha-synuclein and intraepi-
dermal nerve fibers will be performed in four skin punch biop-
sies obtained from the QPART testing sites and two control sites 
(lower legs) as previously described (6). Three-millimeter biop-
sies will be obtained following local anesthesia with 2% lidocaine. 
The procedure was shown to be safe and easy to perform (26). 
Biopsy specimens are fixed in Zamboni solution for 18  h and 
cryoprotected overnight (20% glycerol and 20% 0.4 M Sorensen 
buffer). Tissue blocks are fixed in 10% formalin solution over 
18–24 h at room temperature, then washed, and stored in 0.01 M 
PBS solution at 4°C. Blocks are cut using freezing microtome 
and 20 tissue sections are analyzed. Additional sections are 
analyzed wherever pilomotor muscles or sweat glands are not 
identified in the original sections. All specimens are quantified 
for alpha-synuclein concentrations and pilomotor and sudomo-
tor nerve fiber density by a laboratory experienced in the tech-
nique (Prothena Biosciences Laboratory, South San Francisco, 
CA, USA). Alpha-synuclein/intraepidermal nerve fiber density 
ratios are calculated for pilomotor muscles and sweat glands. The 
procedure has been shown safe; it includes not only reversible 
minimum skin damage and previous studies using the same 
procedure noted no adverse events (4, 6). Specimens will be 
preserved for at least 10 years and will be destroyed if the subject 
withdraws from the study.
Possible pitfalls include damage to the specimen due to incor-
rect removal of the punch. To address this issue investigators who 
will operate the procedure (Martin Arndt, Timo Siepmann) are 
trained by a physician experienced with the technique (BMI). We 
anticipate that alpha-synuclein/intraepidermal nerve fiber den-
sity ratios are increased in pilomotor muscles and sweat glands 
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of patients with PD compared to healthy subjects. We further 
anticipate that this measure of alpha-synuclein damage increases 
over time and is related to functional decline of pilomotor and 
sudomotor nerve fibers.
Evaluation of Motor and Autonomic Symptoms
Progression of motor and autonomic symptoms are assessed 
through validated symptom scores MDS-UPDRS motor part 
(27) and SCOPA-AUT (28, 29). In order to assure precise grad-
ing, investigators performing/evaluating these scales are either 
physicians with experience in the assessment of patients with PD 
(Elka Frenz, Timo Siepmann, Kristian Barlinn) or are be trained 
by these physicians prior to beginning of the study.
statistical considerations
Primary Endpoint and Sample Size Calculation
The absolute number of indirect hair follicle indentations is 
a primary endpoint. The sample size was calculated based on 
an interim analysis of an unpublished pilot study using results 
from assessment of 12 PD patients. A SD of 8.2 was found by 
means of QPART (p < 0.05 PD versus healthy controls). Based 
on this observation, we will be able to detect a difference in 
means of 2.5 (16%) with 90% power at a significance level 
of 0.05 by including 13 subjects and 13 PD patients at each 
participating study site.
Statistical Analysis Plan
Analyses are performed using the statistical software package 
STATA® (Version 14, College Station, TX, USA). Differences 
between groups are analyzed using ANOVA with repeated meas-
ures. Post hoc t-tests are performed where appropriate. Pearson’s 
correlation analyses are performed to assess the relations between 
disease length, motor symptom progression (UPDRS motor part), 
perceived autonomic symptoms (SCOPA-AUT), and progression 
of autonomic small fiber dysfunction. Univariate and multivari-
ate regression models are built to assess whether pilomotor and 
sudomotor functional measures are independently associated 
with autonomic and motor symptom severity. All factors that 
emerge as predictor variables in the univariate analysis at p < 0.1 
are included in the multivariate model as candidate variables 
and then removed by stepwise backward selection procedure with 
removal threshold set at p =  0.2. In addition, a forward selec-
tion procedure will be performed to confirm the robustness of 
the multivariate model. A proximal similarity model is built to 
estimate external validity.
Adverse Events
All subjects will be questioned for adverse events (undesired 
harmful effect resulting from the study procedure) after each 
study procedure. Adverse events are not expected in this study 
as each applied procedure has minimum risks of adverse 
events. Serious adverse events (events resulting in death, 
life-threatening condition, inpatient hospitalization or pro-
longation of existing hospitalization, persistent or significant 
disability/incapacity, the necessity of intervention to prevent 
permanent impairment or damage) are not expected in this 
study, as each applied procedure has minimum risks of serious 
adverse events.
Data Management
All data will be entered into the case report form. The case 
report form will be signed by the study physician and will be 
stored for at least 10  years in the local study archive. All data 
will be pseudonymized and entered into study data base using 
REDCap (Research Electronic Data Capture, ©2015 Vanderbilt 
University), a standardized and secure web application for build-
ing and managing online surveys and databases.
Informed consent
The investigator will obtain informed consent of a subject or 
his/her designee prior to any study-related procedures. The study 
will be explained in detail to the patients by the investigators. In 
addition, each patient will receive detailed study information in 
writing. After all questions have been answered, the patient will 
sign the written informed consent form. One original copy of the 
written informed consent will be kept in the study center and a 
second original copy will be handed out to the patient.
limitations and Potential Pitfalls
This protocol comprises techniques of functional autonomic 
fiber assessment (QPART and QDIRT) that are not the most 
widely used methods of their kind, which might reduce com-
parability with previous research. However, we have specifically 
chosen these techniques as they allow assessment of axon-reflex 
responses with both temporal and spatial resolution. We antici-
pate that this technical feature will help overcome those limita-
tions of axon-reflex assessment that were apparent in previous 
studies applying more conventional techniques. In particular, we 
seek to reduce intraindividual and interindividual variability by 
increasing the dimensions in which the axon-reflex response is 
evaluated. Another possible pitfall of this protocol originates in 
the duration of this longitudinal 3-year study. Namely, there is a 
considerable risk of loss to follow-up due to the relatively long 
intervals between the study visits. Therefore, we plan to increase 
protocol adherence by reaching out to our subject prior to each 
visit both via e-mail and telephone.
INtErPrEtAtIoN oF ANtIcIPAtED 
rEsUlts
Demonstrating generalizability and reproducibility of the 
QPART and the QDIRT technique in a population of PD patients 
might support the potential utility of these techniques in the early 
diagnosis and monitoring of the disease. The anticipated asso-
ciation of functional and structural pilomotor and sudomotor 
nerve fiber impairment might improve our understanding of the 
role of alpha-synuclein-mediated neuropathy in PD support the 
capacity of these techniques to assess specific fiber damage. Both 
QPART and QDIRT might thus provide non-invasive tools for 
interventional studies evaluating disease-modifying approaches 
and clinical assessment of autonomic dysfunction in patients 
with PD.
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